Wedbush initiated coverage on shares of Millendo Therapeutics (NASDAQ:MLND) in a report published on Thursday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $24.00 price target on the stock.

Several other research firms have also recently commented on MLND. Zacks Investment Research upgraded shares of Golub Capital BDC from a hold rating to a buy rating and set a $20.00 price target for the company in a report on Tuesday, July 16th. ValuEngine cut shares of Welbilt from a hold rating to a sell rating in a report on Wednesday, June 12th. CIBC lowered their price target on shares of Stuart Olson from C$5.00 to C$4.00 in a report on Tuesday, July 16th. Oppenheimer started coverage on shares of Neurocrine Biosciences in a report on Tuesday, July 16th. They set an outperform rating and a $100.00 price target for the company. Finally, Citigroup set a $12.00 target price on shares of Controladora Vuela Co Avcn SA CV and gave the company a buy rating in a report on Monday, July 15th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $24.38.

NASDAQ MLND opened at $10.51 on Thursday. The company has a quick ratio of 7.83, a current ratio of 7.83 and a debt-to-equity ratio of 0.02. Millendo Therapeutics has a 52 week low of $6.77 and a 52 week high of $17.34. The business’s 50 day moving average price is $12.56.

Millendo Therapeutics (NASDAQ:MLND) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.08). As a group, research analysts expect that Millendo Therapeutics will post -3.27 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC acquired a new position in shares of Millendo Therapeutics in the 4th quarter valued at $113,000. BlackRock Inc. acquired a new position in shares of Millendo Therapeutics in the 4th quarter valued at $203,000. Worth Venture Partners LLC acquired a new position in shares of Millendo Therapeutics in the 4th quarter valued at $206,000. Private Advisors LLC boosted its holdings in shares of Millendo Therapeutics by 9.1% in the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock valued at $229,000 after buying an additional 1,279 shares in the last quarter. Finally, Tibra Equities Europe Ltd acquired a new position in shares of Millendo Therapeutics in the 1st quarter valued at $303,000. Institutional investors and hedge funds own 44.07% of the company’s stock.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Further Reading: How does the Beige Book influence monetary policy?

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.